HealthMore in Health→
Eli Lilly’s CrossBridge Bio deal keeps oncology dealmaking focused on smaller, targeted bets
Key Takeaways
- Endpoints reported Eli Lilly will acquire CrossBridge Bio for up to $300 million.
- CrossBridge Bio is described as a small Houston startup focused on antibody-drug conjugates.
- The transaction reflects continued strategic interest in oncology platform deals.
- Milestone-based pricing suggests conviction paired with development-stage caution.
DE
DT Editorial Team··via endpoints.news